Statements (89)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:acquired |
gptkb:Sanofi
|
| gptkbp:advocates_for |
supporting hemophilia community
supporting patients' rights |
| gptkbp:ceo |
gptkb:John_Cox
|
| gptkbp:clinical_trial |
ongoing
Phase 3 evidence-based research advancing science phases of trials investigational studies evaluating treatment effectiveness |
| gptkbp:collaborations |
gptkb:Sanofi_Genzyme
collaborative efforts |
| gptkbp:committee |
expert guidance
|
| gptkbp:community_engagement |
patient advocacy groups
|
| gptkbp:community_involvement |
engagement programs
|
| gptkbp:community_support |
engagement with stakeholders
|
| gptkbp:education |
informative resources
|
| gptkbp:employees |
approximately 300
|
| gptkbp:feedback |
gathering insights
|
| gptkbp:financial_performance |
quarterly earnings
publicly reported |
| gptkbp:focus |
gptkb:healthcare_organization
rare blood disorders |
| gptkbp:founded |
gptkb:2017
|
| gptkbp:founder |
gptkb:John_Cox
|
| gptkbp:global_presence |
international markets
|
| gptkbp:governed_by |
ethical practices
strategic partnerships |
| gptkbp:headquarters |
gptkb:Waltham,_Massachusetts
|
| gptkbp:healthcare |
developing new therapies
new treatment modalities focus on patient needs advancing treatment options collaboration with doctors improving access to therapies improving treatment availability |
| https://www.w3.org/2000/01/rdf-schema#label |
Bioverativ
|
| gptkbp:industry |
part of the sector
|
| gptkbp:innovation |
driving advancements
|
| gptkbp:invention |
patents filed
|
| gptkbp:investment |
gptkb:Europe
gptkb:North_America market trends communication with shareholders biotech innovations |
| gptkbp:language |
innovation-driven
|
| gptkbp:language_of_instruction |
innovative therapies
future therapies |
| gptkbp:market |
industry analysis
new therapies ensuring availability of products |
| gptkbp:marketing_strategy |
targeted therapies
|
| gptkbp:mission |
transform the lives of people with hemophilia
|
| gptkbp:partnership |
multiple research institutions
|
| gptkbp:partnerships |
collaborations with hospitals
biopharma collaborations |
| gptkbp:pharmacokinetics |
focus on drug development
|
| gptkbp:population_trend |
industry developments
|
| gptkbp:products |
gptkb:Alprolix
Eloctate |
| gptkbp:provides_information_on |
establishing best practices
|
| gptkbp:publishes |
research findings
|
| gptkbp:receives_funding_from |
grants and investments
|
| gptkbp:regulatory_compliance |
FDA approved
compliance with health authorities filing for approvals |
| gptkbp:research |
advancing medical knowledge
investing in innovation |
| gptkbp:research_and_development |
biopharmaceuticals
|
| gptkbp:research_areas |
hematology
specialty medicines |
| gptkbp:research_focus |
hemophilia treatments
|
| gptkbp:scholarships |
resources for patients
|
| gptkbp:strategic_importance |
expand product offerings
|
| gptkbp:sustainability_initiatives |
corporate responsibility
|
| gptkbp:symbol |
BIVV
|
| gptkbp:team |
experienced executives
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:training |
professional development
|
| gptkbp:treatment |
measuring effectiveness
improved patient health |
| gptkbp:type |
gptkb:Company
|
| gptkbp:type_of_care |
involving patients in decisions
supporting treatment adherence |
| gptkbp:vision |
improve patient outcomes
|